Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Moderna Therapeutics
Moderna Therapeutics
Activities:
Research & Development
Cardiovascular
Digestion
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Moderna announces positive phase 1/2 data for vaccine against Covid-19
Moderna has shared positive phase 1/2 data for its breakthrough combination vaccine against Influenza and Covid-19
Research & Development
How serious is the Pirola strain?
Following the recent news of gradually increasing cases of the new COVID-19 variant Pirola, we sat down with Moderna's VP of Medical Affairs Cesar Sanz Rodriguez to discuss just what people can expect in the coming months
Distribution
Moderna receives positive opinion from the EMA for Spikevax
Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Research & Development
Moderna discusses mRNA technology advances
Announcements on its mRNA tech, vaccine characterisation and biodistribution were made during the company’s Science and Technology Day event
Regulatory
Moderna senior executive to speak at the ISPE conference
As Chief Technical Operations and Quality Officer, Andres is responsible for the supply of products required for the company’s preclinical and clinical development programmes
Manufacturing
Moderna and Thermo Fisher sign long-term manufacturing agreement
Thermo Fisher will provide dedicated capacity for fill-finish services, in addition to inspection, labelling and packaging
Manufacturing
National Resilience to manufacture mRNA for Moderna vaccine
Under the terms of the multi-year agreement, Resilience will produce mRNA for the COVID-19 vaccine at its facility in Mississauga, Ontario in Canada
Subscribe now